For localized information and support, would you like to switch to your country-specific website for {0}?
cobas® eplex system
IVD
For in vitro diagnostic use.
Fast, reliable syndromic testing for informed therapeutic decisions
The cobas® eplex system simplifies and accelerates multiplex molecular diagnostics, from order entry to result reporting. It features true sample-to-answer workflow, bi-directional laboratory information system (LIS) integration, random and continuous access, and a scalable, modular design, to efficiently adapt to peak demand. With less than 1 minute hands-on time and remote service capabilities, the system reduces downtime while streamlining lab operations. By detecting multiple pathogens from a single patient sample in one rapid test, the cobas eplex system minimizes the need for multiple tests, saving both time and resources.
Enhanced efficiency with our comprehensive panels
With high sensitivity and specificity, all of our panels support infection control and enable rapid and effective treatment decisions, supporting clinicians in improving patient outcomes.1-4
The cobas® eplex blood culture identification panels (BCID) aid in detecting bacterial and fungal organisms and antibiotic resistance genes directly from positive blood cultures in about 1.5 hours.2-4 They offer the broadest coverage of organisms and resistance markers that cause bloodstream infections (BSIs), including anaerobes, multidrug-resistant organisms (MDROs), and emerging fungal pathogens.2-6 Their broad coverage means that about 95% of currently identified bloodstream infections can be detected early.*2-4 By enabling fast, targeted therapy, the BCID panels support sepsis management, infection control, and antimicrobial stewardship.
Comprehensive coverage of respiratory pathogens beyond influenza, such as respiratory syncytial virus (RSV) and SARS-CoV-2, is critical in patients at higher risk for complications or more severe infections. The cobas® eplex respiratory pathogen panel 2 (RP2) detects the most common viruses and bacteria causing upper respiratory illness from a single sample in about 1.5 hours.1 This supports effective infection control and respiratory illness management, particularly during high-demand seasons.
To continue addressing the growing demands of diagnostic laboratories, additional panels are in development to expand testing capabilities.**
A sample-to-answer solution
playicon
videoCtrl
/
fullScreen
Update Required
To play the media you will need to either update your browser to a recent version or update your
Flash plugin.
A whole lab in just one tiny cartridge! Watch to learn more about the cobas eplex system, and discover how its easy-to-use workflow, software features, and automated results reporting into the Laboratory Information System (LIS) can benefit your laboratory.
Show video transcript
Use left and right arrow keys to scroll between the tabs
Overview
Technical Documents
Access important product documentation including relevant certificates and other resources.
After clicking below, you will be redirected to eLabDoc, where you can select your local country-specific documents.
Explore the cobas eplex system
Related products
*Based on ePlex Panel inclusivity compared to 2 representative US clinical data sets (not intended as sensitivity/performance claims): i) The GenMark prospective clinical study database (n=1,978); ii) 12 months of BCID clinical isolate data from 5 geographically diverse US hospitals (n=15,793).
**An updated version of the respiratory pathogen panel and a meningitis & encephalitis panel are currently in development and are not available for sale.
†Based on 24 hour day
References:
GenMark Diagnostics, Inc. cobas® eplex respiratory pathogen panel 2 Method Sheet (v2.0). 2025.
GenMark Diagnostics, Inc. cobas® eplex blood culture identification gram-positive (BCID-GP) panel Method Sheet (v1.0). 2024.
GenMark Diagnostics, Inc. cobas® eplex blood culture identification gram-negative (BCID-GN) panel Method Sheet (v1.0). 2024.
GenMark Diagnostics, Inc. cobas® eplex blood culture identification fungal panel (BCID-FP) Package insert. (vC). 2024.
bioMerieux. BioFire Blood Culture Identification 2 (BCID2) Panel package insert. FIT-PRT-0841-02 June 2020.
Nanosphere Verigene Gram-Positive Blood Culture Nucleic Acid Test (BC-GP) package insert. 27- 00030-01, Rev. B; October 2012.
GenMark Diagnostics, Inc. cobas® eplex® System Instrument Software 3.0 User Assistance (v1.0) 2024.
bioMerieux. BIOFIRE FilmArray Torch Operators Manual, HTFA-PRT-0001-09, 2023.
Qiagen, QIAstat-Dx Analyzer 1.0 User Manual, HB-2942-001, 2021.
Makary MA and Michael D. Medical error—the third leading cause of death in the US. BMJ. 2016;353:i2139.
The National Academics of Sciences, Engineering, and Medicine. [Internet; cited 2017 Apr 20]. Available from: https://www.nap.edu/read/9728/chapter/4#39.